Patients + Caregivers
Changing the future of cancer: YOU are not alone
Every year two million Americans leave their doctor’s offices with a cancer diagnosis, changing the course of their lives. In spite of recent treatment advances, over 600,000 Americans die every year from cancer.
We imagine a world where next-generation precision radiopharmaceuticals are available to every cancer patient, making them a pillar of cancer care.
Radioligands are like microscopic, cancer-seeking missiles. Also known as Radioligand Therapy or RLT, they are modern radiopharmaceuticals actively used to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumours (NETs), and prostate cancer.
Radioligand Therapy (RLT)
Compared to chemotherapy, which is not a targeted therapy and can cause extensive damage to healthy tissue and organs, radioligands precisely deliver radiation to tumors, damaging the cancer cells while avoiding surrounding tissues.
What to expect from radioligand therapy
A positron emission tomography (PET) scan will first be performed to tell your doctor if radioligand therapy is right for you.
Most modern radioligands are injected, in a setting you may already be familiar with, such as a local outpatient cancer treatment center. The administration process itself can be quite short, measured in minutes instead of hours, although patients may be required to wait in the clinic for a period of time after the treatment has been administered.
Shortly after injection, the radioligands will begin circulating around the body, seeking out and bonding to receptors that are overexpressed in the tumors. A part of the radioligand called the medical isotope delivers the therapeutic effect by emitting high-energy particles that damage the cancer cells within the tumor.
Although many patients may notice positive changes shortly after their first treatment, most radioligand treatment plans include multiple injections over a prescribed schedule.
Talk to your doctors
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. We are currently in the research and development phase and do not have any approved products which can be offered for prescription or sale.
We are currently conducting clinical trials to evaluate the safety and efficacy of many of the programs in our pipeline. Talk to your doctor about whether participating in a clinical trial is right for you.